Novel Cancer Antiangiotherapy Using the VEGF Promoter-targeted Artificial Zinc-finger Protein and Oncolytic Adenovirus
Yoon-A Kang(Yonsei University), Chae‐Ok Yun(Hanyang University), Joo-Hang Kim(CHA University Bundang Medical Center), Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Hyun-Chul Shin(Korea National University of Education)
Cited by 55
Related Papers
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth
|Cancer Cell|2015|336
Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
|Clinical Cancer Research|2016|332
VEGF-specific Short Hairpin RNA–expressing Oncolytic Adenovirus Elicits Potent Inhibition of Angiogenesis and Tumor Growth
|Molecular Therapy|2007|150
RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21
|Molecular Therapy|2017|147